Stoke Therapeutics, Inc. STOK ADOA — Operating Expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s adoa — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s ADOA — operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported ADOA — operating expenses of -$1.86M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s ADOA — operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s ADOA — operating expenses decreased by 54.8% year-over-year, from -$1.2M to -$1.86M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s ADOA — operating expenses?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s ADOA — operating expenses has grown at a -13.0% compound annual growth rate (CAGR), from -$8.14M to -$6.16M.
- What does ADOA — operating expenses mean?
- This metric represents the total costs incurred specifically by the ADOA segment to support its research, development, and operational activities. It captures the resources consumed in advancing this specific therapeutic program through its clinical or preclinical lifecycle. Monitoring these expenses helps investors evaluate the capital intensity and resource allocation efficiency dedicated to this particular pipeline asset.